|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,503.00 INR | +1.66% |
|
+5.38% | +13.95% |
| 23/04 | CARE Ratings Assigns AA+ Rating to Mankind Pharma's Bank Facilities; Shares Up 3% | MT |
| 19/03 | Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India | RE |
| Capitalization | 1,03300Cr 1.08TCr 926.05Cr 846.38Cr 808.05Cr 1.48TCr 1.51TCr 10TCr 3.93TCr 49TCr 4.04TCr 3.95TCr 1,71000Cr | P/E ratio 2026 * |
55.7x | P/E ratio 2027 * | 42.8x |
|---|---|---|---|---|---|
| Enterprise value | 1,09100Cr 1.14TCr 977.92Cr 893.79Cr 853.31Cr 1.56TCr 1.59TCr 11TCr 4.15TCr 52TCr 4.27TCr 4.18TCr 1,80500Cr | EV / Sales 2026 * |
7.65x | EV / Sales 2027 * | 6.66x |
| Free-Float |
22.83% | Yield 2026 * |
0.16% | Yield 2027 * | 0.25% |
Last Transcript: Mankind Pharma Limited
| 1 day | +1.66% | ||
| 1 week | +5.38% | ||
| Current month | +11.41% | ||
| 1 month | +20.49% | ||
| 3 months | +21.48% | ||
| 6 months | +10.41% | ||
| Current year | +13.95% |
| 1 week | 2,352.1 |  | 2,534.9 |
| 1 month | 2,094 | | 2,534.9 |
| Current year | 1,909.7 | | 2,534.9 |
| 1 year | 1,909.7 | | 2,716.5 |
| 3 years | 1,242 | | 3,054.8 |
| 5 years | 1,242 | | 3,054.8 |
| 10 years | 1,242 | | 3,054.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sheetal Arora
CEO | Chief Executive Officer | 50 | 21/09/2007 |
Ashutosh Dhawan
DFI | Director of Finance/CFO | 57 | 03/03/2016 |
Anil Kumar
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/2011 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 03/07/1991 | |
Rajeev Juneja
BRD | Director/Board Member | 60 | 22/12/1992 |
Sheetal Arora
BRD | Director/Board Member | 50 | 21/09/2007 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.66% | +5.38% | -2.02% | +79.50% | 1.06TCr | |
| -0.00% | +3.07% | +40.44% | +131.32% | 90TCr | |
| -1.77% | +1.89% | +54.90% | +41.01% | 56TCr | |
| -0.18% | +3.79% | +18.57% | +42.98% | 37TCr | |
| +0.88% | +1.41% | +26.84% | +13.36% | 33TCr | |
| -0.79% | +2.39% | +36.02% | +13.51% | 29TCr | |
| -0.10% | +2.98% | +30.60% | +26.10% | 28TCr | |
| -1.79% | -0.82% | +51.60% | -4.92% | 28TCr | |
| +0.91% | +1.25% | -30.88% | -49.10% | 21TCr | |
| -2.22% | -0.84% | +24.41% | +40.08% | 18TCr | |
| Average | +0.11% | +2.53% | +25.05% | +33.38% | 34.03TCr | |
| Weighted average by Cap. | -0.06% | +2.64% | +33.50% | +49.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 14TCr 148.73Cr 127.9Cr 116.89Cr 111.6Cr 204.5Cr 208.07Cr 1.4TCr 542.58Cr 6.77TCr 558.1Cr 546.22Cr 24TCr | 16TCr 166.17Cr 142.89Cr 130.6Cr 124.68Cr 228.48Cr 232.47Cr 1.57TCr 606.2Cr 7.56TCr 623.53Cr 610.26Cr 26TCr |
| Net income | 1.83TCr 19Cr 16Cr 15Cr 14Cr 26Cr 27Cr 179.5Cr 69Cr 865.45Cr 71Cr 70Cr 3.02TCr | 2.42TCr 25Cr 22Cr 20Cr 19Cr 35Cr 35Cr 237.54Cr 92Cr 1.15TCr 94Cr 92Cr 4TCr |
| Net Debt | 5.79TCr 60Cr 52Cr 47Cr 45Cr 83Cr 84Cr 569.07Cr 220.04Cr 2.74TCr 226.34Cr 221.52Cr 9.58TCr | 2.92TCr 30Cr 26Cr 24Cr 23Cr 42Cr 43Cr 287.47Cr 111.16Cr 1.39TCr 114.33Cr 111.9Cr 4.84TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | 2,503.00 ₹ | +1.66% | 11,20,942 |
| 14/26/14 | 2,462.20 ₹ | +2.27% | 4,97,725 |
| 13/26/13 | 2,407.60 ₹ | +1.21% | 5,95,559 |
| 12/26/12 | 2,378.90 ₹ | -3.64% | 5,53,734 |
| 11/26/11 | 2,468.80 ₹ | +1.56% | 6,72,282 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MANKIND Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition